Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAX2 in Relapsed/Refractory Advanced/Metastatic Solid Tumours
NCT07688148Phase 2Not yet recruiting
- Sponsor
- Apmonia Therapeutics
- Start
- Oct 2026
- Primary completion
- Feb 2029
- Countries
- 2
01
Overview
A Phase 2 trial of TAX2 in solid tumor, sponsored by Apmonia Therapeutics. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
TAX2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07688148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07688148.